Literature DB >> 17090553

Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England.

Neil Woodford1, Mary E Kaufmann, Edi Karisik, John W Hartley.   

Abstract

OBJECTIVES: To study the clonality of gentamicin-resistant, extended-spectrum beta-lactamase (ESBL)-negative and ESBL-producing Escherichia coli isolated from community-onset urinary tract infections (UTIs) in Cornwall.
METHODS: Isolates were identified by API, susceptibilities were determined by local disc testing, and MICs were determined at the reference laboratory, both interpreted using BSAC guidelines. bla(CTX-M) genes were sought by PCR, and isolates were compared by PFGE.
RESULTS: In the years 2004 and 2005, 69 E. coli were submitted by Truro (Cornwall) laboratory for reference laboratory testing: these included 14 gentamicin-resistant, ESBL-negative isolates; 45 with group 1 CTX-M enzymes; seven with group 9 CTX-M enzymes; and three with non-CTX-M ESBLs. By PFGE, nine gentamicin-resistant, ESBL-negative E. coli were distinct (<85% similarity) from all the ESBL producers, but three were related to producers of group 1 CTX-M enzymes, and two isolates were related to a non-CTX-M ESBL producer. An outbreak strain was identified, represented by 11 gentamicin-resistant and one gentamicin-susceptible isolates, all with group 1 CTX-M enzymes, and two gentamicin-resistant, ESBL-negative isolates. This was distinct by PFGE from nationally distributed CTX-M-producing strains. Five of nine patients infected with this strain had been on the same ward in a local hospital; four presented with community-onset UTIs; one inpatient developed a hospital-acquired bacteraemia. Of the other four patients presenting with community-onset UTIs, three were admitted to different hospitals and the fourth had only attended an outpatient clinic.
CONCLUSIONS: Community-onset, ESBL-producing and non-producing E. coli were diverse. Two ESBL-negative isolates were closely related to a local CTX-M-producing outbreak strain, suggesting gain or loss of a bla(CTX-M)-carrying plasmid. An outbreak strain was linked with prior hospital admission and appeared not to represent genuine community acquisition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090553     DOI: 10.1093/jac/dkl435

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.

Authors:  Christopher R Bethel; Magdalena Taracila; Teresa Shyr; Jodi M Thomson; Anne M Distler; Kristine M Hujer; Andrea M Hujer; Andrea Endimiani; Krisztina Papp-Wallace; Richard Bonnet; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

2.  Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States.

Authors:  Yohei Doi; Yoon Soo Park; Jesabel I Rivera; Jennifer M Adams-Haduch; Ameet Hingwe; Emilia M Sordillo; James S Lewis; Wanita J Howard; Laura E Johnson; Bruce Polsky; James H Jorgensen; Sandra S Richter; Kathleen A Shutt; David L Paterson
Journal:  Clin Infect Dis       Date:  2012-11-13       Impact factor: 9.079

3.  Chicken as reservoir for extraintestinal pathogenic Escherichia coli in humans, Canada.

Authors:  Catherine Racicot Bergeron; Catharine Prussing; Patrick Boerlin; Danielle Daignault; Lucie Dutil; Richard J Reid-Smith; George G Zhanel; Amee R Manges
Journal:  Emerg Infect Dis       Date:  2012-03       Impact factor: 6.883

4.  Foodborne urinary tract infections: a new paradigm for antimicrobial-resistant foodborne illness.

Authors:  Lora Nordstrom; Cindy M Liu; Lance B Price
Journal:  Front Microbiol       Date:  2013-03-06       Impact factor: 5.640

5.  Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections.

Authors:  Amee R Manges; Helen Tabor; Patricia Tellis; Caroline Vincent; Pierre-Paul Tellier
Journal:  Emerg Infect Dis       Date:  2008-10       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.